Drug Profile
Research programme: antibacterials - PALUMED
Alternative Names: Antibioquines; Hybrid antibacterials - PALUMED; PA 1046; PA 1409; Vancomyquine; Vancomyquine PA1409 (anti-MRSA drug)Latest Information Update: 08 Jul 2016
Price :
$50
*
At a glance
- Originator PALUMED
- Class Aminoquinolines; Cephalosporins; Glycopeptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 15 Sep 2009 Preclinical trials in Meticillin-resistant Staphylococcus aureus infections in France (unspecified route)
- 15 Sep 2009 Antimicrobial, pharmacokinetic & pharmacodynamic data from preclinical trials of PA 1409 in Bacterial infections (including MRSA) presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,,
- 21 Feb 2007 Preclinical trials in Bacterial infections in France (unspecified route)